Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs & Therapy Perspectives
Erschienen in: Drugs & Therapy Perspectives 9/2018

01.09.2018 | Adis Drug Q&A

Hialid®/Hyalein® (sodium hyaluronate) ophthalmic solution in dry eye syndrome: a profile of its use

verfasst von: Kate McKeage, Katherine A. Lyseng-Williamson

Erschienen in: Drugs & Therapy Perspectives | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Hialid®/Hyalein® (also known as Sanlein®) is an effective and well tolerated ophthalmic solution for the treatment of keratoconjunctival epithelial disorder associated with dry eye syndrome. Hialid®/Hyalein® contains the active ingredient sodium hyaluronate, a natural component of tear film, which has high water retention ability, increases tear film stability and accelerates corneal wound healing. One drop in each eye 5–6 times daily improves the symptoms of dry eye, as well as objective measures of corneal staining. The efficacy of the solution is noninferior to that of ciclosporin 0.05% anionic emulsion eye drops in this patient population.
Literatur
1.
Chao W, Belmonte C, Benitez Del Castillo JM, et al. Report of the inaugural meeting of the TFOS i2 = initiating innovation series: targeting the unmet need for dry eye treatment. Ocul Surf. 2016;14(2):264–316.CrossRefPubMed
2.
Lienert JP, Tarko L, Uchino M, et al. Long-term natural history of dry eye disease from the patient’s perspective. Ophthalmology. 2016;123(2):425–33.CrossRefPubMed
3.
4.
Skalicky SE, Petsoglou C, Gurbaxani A, et al. New agents for treating dry eye syndrome. Curr Allergy Asthma Rep. 2013;13(3):322–8.CrossRefPubMed
5.
Johnson ME, Murphy PJ, Boulton M. Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye. Graefes Arch Clin Exp Ophthalmol. 2006;244(1):109–12.CrossRefPubMed
6.
Hyalein® opthalmic solution 0.1% and mini opthalmic solution 0.1% and 03%: product insert. Osaka: Santen Pharmaceutical Co., Ltd. 2010.
7.
Nakamura M, Hikida M, Nakano T, et al. Characterization of water retentive properties of hyaluronan. Cornea. 1993;12:433–6.CrossRefPubMed
8.
Tsubota K, Yamada M. Tear evaporation from the ocular surface. Invest Ophthalmol Vis Sci. 1992;33(10):2942–50.PubMed
9.
Snibson GR, Greaves JL, Soper ND, et al. Precorneal residence times of sodium hyaluronate solutions studied by quantitative gamma scintigraphy. Eye (Lond). 1990;4(Pt 4):594–602.CrossRefPubMed
10.
Nam KT, Ahn SM, Eom Y, et al. Immediate effects of 3% diquafosol and 0.1% hyaluronic acid ophthalmic solution on tear break-up time in normal human eyes. J Ocul Pharmacol Ther. 2015;31(10):631–5.CrossRefPubMed
11.
Aragona P, Di Stefano G, Ferreri F, et al. Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjogren’s syndrome patients. Br J Ophthalmol. 2002;86(8):879–84.CrossRefPubMedPubMedCentral
12.
Gurny R, Ryser JE, Tabatabay C, et al. Precorneal residence time in humans of sodium hyaluronate as measured by gamma scintigraphy. Graefes Arch Clin Exp Ophthalmol. 1990;228(6):510–2.CrossRefPubMed
13.
Hamano T, Horimoto K, Lee M, et al. Sodium hyaluronate eyedrops enhance tear film stability. Jpn J Ophthalmol. 1996;40(1):62–5.PubMed
14.
Li Y, Sang X, Yang L, et al. Low concentration of sodium hyaluronate temporarily elevates the tear film lipid layer thickness in dry eye patients with lipid deficiency. J Ophthalmol. 2018;1(3):389–94.
15.
Lee JS, Lee SU, Che CY, et al. Comparison of cytotoxicity and wound healing effect of carboxymethylcelluose and hyaluronic acid on human corneal epithelial cells. J Ophthalmol. 2015;8(2):215–21.
16.
Lee JH, Lee JS, Kim S, et al. Comparison of cytotoxicities and wound healing effects of diquafosol tetrasodium and hyaluronic acid on human corneal epithelial cells. Koren J Physiol Pharmacol. 2017;21(2):189–95.CrossRef
17.
Camillieri G, Bucolo C, Rossi S, et al. Hyaluronan-induced stimulation of corneal wound healing is a pure pharmacological effect. J Ocul Pharmacol Ther. 2004;20(6):548–53.CrossRefPubMed
18.
Inoue M, Katakami C. The effect of hyaluronic acid on corneal epithelial cell proliferation. Invest Ophthalmol Vis Sci. 1993;34(7):13–5.
19.
Gomes JA, Amankwah R, Powell-Richards A, et al. Sodium hyaluronate (hyaluronic acid) promotes migration of human corneal epithelial cells in vitro. Br J Ophthalmol. 2004;88(6):821–5.CrossRefPubMedPubMedCentral
20.
Yu F, Liu X, Zhong Y, et al. Sodium hyaluronate decreases ocular surface toxicity induced by benzalkoniium chloride-preserved latanoprost: an in vivo study. Invest Opthalmol Vis Sci. 2013;54(5):3385–92.CrossRef
21.
Araki R, Nakashima M, Teshima M, et al. Investigation of protective effects of sodium hyaluronate eyedrop against corneal epithelial disorders using an electrophysiological method. J Ocul Pharmacol Ther. 2012;28(3):251–8.CrossRefPubMed
22.
Ye J, Zhang H, Wu H, et al. Cytoprotective effect of hyaluronic acid and hydroxypropyl methylcellulose against DNA damage induced by thimerosal in Chang conjunctival cells. Graefes Arch Clin Exp Ophthalmol. 2012;250(10):1459–66.CrossRefPubMed
23.
Hyalein®/Hialid®/Sanlein®: information for patients. Osaka: Santen Pharmaceutical Co., Ltd.. 2017.
24.
Hialid 0.1/0.3 ophthalmic solution (sodium hyaluronate): prescribing information (Indonesia). Osaka: Santen Pharmaceutical Co., Ltd.. 2017.
25.
Park Y, Song JS, Choi CY, et al. A randomized multicenter study comparing 0.1%, 0.15%, and 0.3% sodium hyaluronate with 0.05% cyclosporine in the treatment of dry eye. J Ocul Pharmacol Ther. 2017;33(2):66–72.CrossRefPubMedPubMedCentral
26.
Ang BCH, Sng JJ, Wang PXH, et al. Sodium hyaluronate in the treatment of dry eye syndrome: a systematic review and meta-analysis. Sci Rep. 2017; 7.
27.
Liu X, Yu FF, Zhong YM, et al. Therapeutic effects of sodium hyaluronate on ocular surface damage induced by benzalkonium chloride preserved anti-glaucoma medications. Chin Med J. 2015;128(18):2444–9.CrossRefPubMedPubMedCentral
28.
Kitano S, Otori T, Masuda K. Clinical effect of sodium hyaluronate ophthalmic solution on keratoconjunctival epithelial disorders: comparative study with glutathione ophthalmic solution [in Japanese]. Folia Ophthalmol Jpn. 1993;44(4):487–97.
29.
Lee JH, Ahn HS, Kim EK, et al. Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease. Cornea. 2011;30(2):175–9.CrossRefPubMed
30.
Takamura T, Tsobota K, Watanabe H, et al. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012;96(10):1310–5.CrossRefPubMedPubMedCentral
31.
Matsuo T. Trehalose versus hyaluronan or cellulose in eyedrops for the treatment of dry eye. Jpn J Ophthalmol. 2004;48(4):321–7.CrossRefPubMed
32.
Lin T, Gong L. Sodium hyaluronate eye drops treatment for superficial corneal abrasion caused by mechanical damage: a randomized clinical trial in the People’s Republic of China. Drug Des Devel Ther. 2015;9:687–94.CrossRefPubMedPubMedCentral
33.
Hwang HS, Sung YM, Lee WS, et al. Additive effect of preservative-free sodium hyaluronate 0.1% in treatment of dry eye syndrome with diquafosol 3% eye drops. Cornea. 2014;33(9):935–41.CrossRefPubMed
34.
Kamiya K, Nakanishi M, Ishii R, et al. Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. Eye (Lond). 2012;26(10):1363–8.CrossRefPubMedPubMedCentral
35.
Data on file. Osaka: Santen Pharmaceutical Co., Ltd. 2018.
36.
Kitano S, Otori T, Masuda K. Effect of 0.3% sodium hyluronate opthalmic solution on severe keratoconjunctival epithelial disorders [in Japanese]. Atarashii. Ganka. 1993;10(4):603–10.
37.
Yamamoto T, Wada M, Nakai N, et al. Allergic contact dermatitis due to epsilon-aminocaproic acid: a case report and mini-review of the published work. J Dermatol. 2013;40(4):301–3.CrossRefPubMed
38.
Mitsuyama S, Abe F, Masaaki K, et al. Allergic contact dermatitis caused by ε-aminocaproic acid in a purified sodium hyaluronate ophthalmic solution. Contact Dermatitis. 2017;77(3):191–2.CrossRefPubMed
39.
Sukegawa T. A case of allergic contact dermatitis due to unit dose type purified sodium hyaluronate ophthalmic solution [in Japanese]. Nippon Ganka Gakkai Zasshi. 2014;118(2):111–5.PubMed
Metadaten
Titel
Hialid®/Hyalein® (sodium hyaluronate) ophthalmic solution in dry eye syndrome: a profile of its use
verfasst von
Kate McKeage
Katherine A. Lyseng-Williamson
Publikationsdatum
01.09.2018
Verlag
Springer International Publishing
Erschienen in
Drugs & Therapy Perspectives / Ausgabe 9/2018
Print ISSN: 1172-0360
Elektronische ISSN: 1179-1977
DOI
https://doi.org/10.1007/s40267-018-0540-0

Weitere Artikel der Ausgabe 9/2018

Drugs & Therapy Perspectives 9/2018 Zur Ausgabe

Original Research Article

Associations between Drug Burden Index, medication appropriateness and patient-reported outcomes in the community pharmacy setting in Malaysia

Review Article

Phenobarbital monotherapy for alcohol withdrawal syndrome in the non-intensive care unit setting: a review

Adis Drug Q&A

Amphetamine extended-release oral suspension (Adzenys ER™) and orally disintegrating tablets (Adzenys XR-ODT®) in attention-deficit hyperactivity disorder: a profile of their use

Practical Issues and Updates

Tattooing is possible in many patients with medical or skin conditions as long as disease-specific recommendations are followed

Drug Reactions and Interactions

Preventing and managing dimethyl fumarate-related adverse effects in patients with multiple sclerosis may improve adherence

Original Research Article

Management and outcome of Stevens–Johnson syndrome and toxic epidermal necrolysis in patients admitted to Kenyatta National Hospital